Randomized trial demonstrates sustained symptom relief in cancer survivors with neuropathy, indicating durable benefits from acupressure.
Key Points
To evaluate the sustainability of symptom improvements over three months following a four-week auricular point acupressure intervention for chemotherapy-induced neuropathy.
Prespecified secondary analysis of a randomized wait-list controlled trial (NCT04920097) comparing mobile-supported acupressure (mAPA, n = 80) and virtual acupressure (vAPA, n = 75) in adults with moderate or greater chemotherapy-induced neuropathy.
Assessed neuropathy severity via an individualized composite outcome and symptom interference at one, two, and three months post-intervention using generalized estimating equations with multiple imputation.
Reductions in neuropathy severity and interference were significantly sustained throughout the three-month follow-up across both groups (all p < .001).
Individualized composite outcome scores decreased by 3.10, 3.36, and 3.61 points in mAPA and by 2.88, 2.90, and 3.21 points in vAPA at 1, 2, and 3 months post-intervention, respectively.